Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Spotlight Correspondence
  • Published:

Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8

Leukemia volume 16, pages 1390–1393 (2002)Cite this article

Chronic myeloid leukemia (CML) is characterized by the Philadelphia chromosome (Ph), the chromosome 22 derivative of the balanced translocation, t(9;22)(q34;q11). By fusing the ABL gene on 9q34 to the BCR gene on 22q11, the abl tyrosine kinase is constitutively activated1 causing proliferation and accumulation of immature and mature myeloid cells in blood and bone marrow. The Philadelphia chromosome and the BCR/ABL transcript are important markers in diagnosing and monitoring cytogenetic and molecular response to treatment in CML.

Therapy with conventional cytostatic agents, such as hydroxurea and busulfan, is able to normalize blood cell counts and eliminate splenomegaly. However, the Ph-positive clone persists in blood and bone marrow cells.2,3 More recent types of treatment, such as IFN and the tyrosine kinase inhibitor, imatinib mesylate, have the potential to induce cytogenetic remission with disappearance of the Ph chromosome4,5, but molecular remissions are rare.6 So far, only allogeneic bone marrow transplantation (ABMT) has been able to induce permanent molecular remission in larger series of patients with CML.7

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Kalidas M, Kantarjian H, Talpaz M . Chronic myeloid leukemia JAMA 2001 286: 895–898

    Article  CAS  Google Scholar 

  2. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queisser W, Loffler H, Heinze B, Georgii A . Randomized comparison of busulfan and hydroxurea in chronic myelogeneous leukaemia: prolongation of survival by hydroxurea. The German CML Study Group Blood 1993 82: 398–407

    CAS  PubMed  Google Scholar 

  3. Hehlman R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queisser W, Loffler H, Hochhaus A, Heinze B . Randomized comparison of interferon-alpha with busulfan and hydroxurea in chronic myelogeneous leukaemia. The German CML Study Group Blood 1994 84: 4064–4077

    Google Scholar 

  4. Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU . Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogeneous leukemia N Engl J Med 1986 314: 1065–1069

    Article  CAS  Google Scholar 

  5. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL . Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 2001 344: 1031–1037

    Article  CAS  Google Scholar 

  6. Mahon FX, Delbrel X, Cony-Makhoul P, Faberes C, Boiron JM, Barthe C, Bilhou-Nabera C, Pigneux A, Mait G, Reiffers J . Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa J Clin Oncol 2002 20: 214–220

    Article  CAS  Google Scholar 

  7. Horowitz MM, Rowlings PA, Passweg JR . Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry Bone Marrow Transplant 1996 17 (Suppl. 3): S5–S6

    Google Scholar 

  8. Casali M, Truglio F, Milone G, Di Raimondo F, Parrinello G, Maserati E, Pasquali F . Trisomy 8 in Philadelphia chromosome (Ph1)-negative cells in the course of Ph1-positive chronic myelocytic leukemia Genes Chromosomes Cancer 1992 4: 269–270

    Article  CAS  Google Scholar 

  9. Bilhou-Nabera C, Marit G, Devianne I, Viard F, Salzes S, Montastruc M, Renoux M, Broustet A, Reiffers J, Bernard P . A second case of trisomy 8 in Philadelphia chromosome (Ph)-negative cells during the course of Ph-positive chronic myelocytic leukemia Genes Chromosomes Cancer 1993 4: 255–256

    Article  Google Scholar 

  10. Ariyama T, Inazawa J, Uemura Y, Kakazu N, Maekawa T, Urase F, Irimajiri K, Horiuchi A, Nakamura Y, Abe T . Clonal origin of Philadelphia chromosome negative cells with trisomy 8 appearing during the course of α-interferon therapy for Ph positive chronic myelocytic leukemia Cancer Genet Cytogenet 1995 81: 20–23

    Article  CAS  Google Scholar 

  11. Ohtsuka E, Kikuchi H, Abe Y, Moriyama K, Ohno E, Hirota K, Tezono K, Nasu M . Acute myeloblastic leukaemia without Philadelphia chromosome developing after interferon therapy for chronic myelocytic leukaemia with Philadelphia chromosome Br J Haematol 1995 90: 951–953

    Article  CAS  Google Scholar 

  12. Izumi T, Imagawa S, Hatake K, Miura Y, Ariyama T, Inazawa J, Abe T . Philadelphia chromosome-negative cells with trisomy 8 after busulfan and interferon treatment of Ph1-positive chronic myelogenous leukemia Int J Hematol 1996 64: 73–77

    Article  CAS  Google Scholar 

  13. Fayad L, Kantarjian H, O'Brien S, Seong D, Keating M, Talpaz M . Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases Leukemia 1997 11: 767–771

    Article  CAS  Google Scholar 

  14. Marktel S, Bua M, Marin D, Chase A, Udom C, Armstrong L, Apperley JF, Olavarria E, Goldman JM . Emergence of additional chromosomal abnormalities following treatment with STI571 (Imatinib Mesylate) for Philadelphia positive chronic myeloid leukemia in chronic phase Blood 2001 98: 617a (Abstra. 2584)

    Google Scholar 

  15. Gambacorti-Passeri C, Giudici G, le Coutre P, Bungaro S, Pogliani EM, Kreuzer K-A, Tornaghi L, Alberti D, Corneo G, Biondi A . Non random chromosomal abnormalities in Ph-negative bone marrow (BM) cells from CML patients achieving major cytogenetic responses (MCR) with STI571 (Gleevec™) Blood 2001 98: 257b (Abstr. 4762)

    Article  Google Scholar 

  16. Meunier V, Giraudier S, Van den Akker J, Perot C, Jouault H, Caron-Servan B, Robin V, Tulliez M, Imbert M . Treatment with STI571 (Novartis®) in chronic myeloid leukemia (CML): unexpected hematological findings in a series of 26 patients Blood 2001 98: 263b (Abstr. 4784)

    Google Scholar 

  17. Fialkow PJ, Martin PJ, Najfeld V, Penfold GK, Jacobsen RJ, Hansen JA . Evidence for a multistep pathogenesis of chronic myelogeneous leukemia Blood 1981 58: 158–163

    CAS  PubMed  Google Scholar 

  18. Raskind WH, Ferraris AM, Najfeld V, Jacobsen RJ, Moohr JW, Fialkow PJ . Further evidence of a clonal Ph-negative stage in some cases of Ph-positive chronic myelocytic leukemia Leukemia 1993 7: 1163–1167

    CAS  PubMed  Google Scholar 

  19. Ferraris AM, Canepa L, Melani C, Miglino M, Broccia G, Gaetani GF . Clonal B lymphocytes lack bcr rearrangement in Ph-positive chronic myelogenous leukaemia Br J Haematol 1989 73: 48–50

    Article  CAS  Google Scholar 

  20. Lisker R, Casas L, Mutchinick O, Perez-Chavez F, Labardini J . Late-appearing Philadelphia chromosome in two patients with chronic myelogenous leukemia Blood 1980 56: 812–814

    CAS  PubMed  Google Scholar 

  21. Virtaneva K, Wright FA, Tanner SM, Yuan B, Lemon WJ, Caligiuri MA, Bloomfield CD, de La Chapelle A, Krahe R . Expression profiling reveals biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics Proc Natl Acad Sci USA 2001 98: 1124–1129

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Genetics, The Cytogenetic Laboratory, Section of Hematology/Oncology, Rigshospitalet, Copenhagen, Denmark

    MK Andersen & J Pedersen-Bjergaard

  2. Department of Hematology, Rigshospitalet, Copenhagen, Denmark

    L Kjeldsen

  3. Department of Hematology, Amtssygehuset Herlev, Denmark

    IH Dufva

  4. John F Kennedy Institute, Glostrup, Denmark

    K Brøndum-Nielsen

Authors
  1. MK Andersen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Pedersen-Bjergaard
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L Kjeldsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. IH Dufva
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K Brøndum-Nielsen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Andersen, M., Pedersen-Bjergaard, J., Kjeldsen, L. et al. Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8. Leukemia 16, 1390–1393 (2002). https://doi.org/10.1038/sj.leu.2402634

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402634

This article is cited by

Search

Advanced search

Quick links